Citation Impact
Citing Papers
Vaccine-delivered HIV envelope inhibits CD4+ T-cell activation, a mechanism for poor HIV vaccine responses
2006 StandoutNobel
Species-Specific Recognition of Single-Stranded RNA via Toll-like Receptor 7 and 8
2004 StandoutScience
Small Interfering RNAs Mediate Sequence-Independent Gene Suppression and Induce Immune Activation by Signaling through Toll-Like Receptor 3
2004 StandoutNobel
Dendritic Cell Targeting of Survivin Protein in a Xenogeneic Form Elicits Strong CD4+ T Cell Immunity to Mouse Survivin
2006 StandoutNobel
Cancer immunoediting: from immunosurveillance to tumor escape
2002 Standout
Survival Effect of Maximal Cytoreductive Surgery for Advanced Ovarian Carcinoma During the Platinum Era: A Meta-Analysis
2002 Standout
EGFR Antagonists in Cancer Treatment
2008 Standout
Immunosuppressive networks in the tumour environment and their therapeutic relevance
2005 Standout
mRNA Is an Endogenous Ligand for Toll-like Receptor 3
2004 StandoutNobel
A randomized trial of cyclophosphamide, doxorubicin, and cisplatin with or without bacillus Calmette-Guerin in patients with suboptimal stage III and IV ovarian cancer: A Gynecologic Oncology Group Study
1990
mRNA-based therapeutics — developing a new class of drugs
2014 StandoutNobel
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
2019 Standout
Granulocyte-Macrophage Colony-Stimulating Factor Gene-Modified Autologous Tumor Vaccines in Non-Small-Cell Lung Cancer
2004
Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative.
1996 Standout
High-dose methotrexate: a critical reappraisal.
1987
SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials
2013 Standout
Head and neck cancer
2008 Standout
Cancer immunotherapy: breaking the barriers to harvest the crop
2004 StandoutNobel
Renal-Cell Carcinoma
1996 Standout
Cancer immunotherapy via dendritic cells
2012 Standout
Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
2007 Standout
Phase I Trial of Large Multivalent Immunogen Derived from Melanoma Lysates in Patients with Disseminated Melanoma
2004
Incorporation of pseudouridine into mRNA enhances translation by diminishing PKR activation
2010 StandoutNobel
Membrane vesicles as conveyors of immune responses
2009 Standout
Antibody therapy of cancer
2012 Standout
Interferon‐alpha and survival in renal cell cancer
1995
Regulatory T cells, tumour immunity and immunotherapy
2006 Standout
Management of Cutaneous Melanoma
2004
Cancer immunotherapy: moving beyond current vaccines
2004 Standout
Inhibition of N‐methyl‐N′'‐nitro‐n‐nitrosoguanidine‐induced methotrexate and adriamycin resistance in CHO cells by adeno‐associated virus type 2
1990 StandoutNobel
Chemotherapy and the war on cancer
2005 Standout
Translation of new cancer treatments from pet dogs to humans
2008 Standout
Modulating T-cell immunity to tumours: new strategies for monitoring T-cell responses
2002
A new synthetic TLR4 agonist, GLA, allows dendritic cells targeted with antigen to elicit Th1 T‐cell immunity in vivo
2011 StandoutNobel
Cancer vaccines: between the idea and the reality
2003
Determination of methotrexate in environmental samples by solid phase extraction and high performance liquid chromatography: ultraviolet or tandem mass spectrometry detection?
2000
Head and Neck Cancer
1993 Standout
Suppression of RNA Recognition by Toll-like Receptors: The Impact of Nucleoside Modification and the Evolutionary Origin of RNA
2005 StandoutNobel
Antitumor immune response by CX3CL1 fractalkine gene transfer depends on both NK and T cells
2005 StandoutNobel
Extracellular mRNA Induces Dendritic Cell Activation by Stimulating Tumor Necrosis Factor-α Secretion and Signaling through a Nucleotide Receptor
2002 StandoutNobel
Adjuvant therapy for high‐risk primary and resected metastatic melanoma
2003
Prevention of Second Primary Tumors with Isotretinoin in Squamous-Cell Carcinoma of the Head and Neck
1990 Standout
TLR-based immune adjuvants
2010
Enhanced induction of dendritic cell maturation and HLA-A*0201-restricted CEA-specific CD8+ CTL response by exosomes derived from IL-18 gene-modified CEA-positive tumor cells
2006
Adherence to Medication
2005 Standout
Selective dna‐amplification induced by carcinogens (initiators): Evidence for a role of proteases and DNA polymerase alpha
1985 StandoutNobel
Current Developments in Cancer Vaccines and Cellular Immunotherapy
2003
Early protection against pathogenic virus infection at a mucosal challenge site after vaccination with attenuated simian immunodeficiency virus
2004 StandoutNobel
Graphene Oxide: Preparation, Functionalization, and Electrochemical Applications
2012 Standout
Changing role of chemotherapy in treatment of head and neck cancer
1982
Chemotherapy in Head and Neck Cancer
1983
THE EFFECT OF AMETHOPTERIN ON THE IMMUNE RESPONSE*
1971 StandoutNobel
The Pharmacology and Clinical Use of Methotrexate
1983
Vaccination with human tyrosinase DNA induces antibody responses in dogs with advanced melanoma.
2006
Gene amplification, drug resistance, and cancer.
1984
Methotrexate: clinical pharmacology, current status and therapeutic guidelines
1977
The Effect of Adjuvant Chemotherapy on Relapse-Free Survival in Patients with Osteosarcoma of the Extremity
1986 Standout
Immunosuppressive Effects of Cytosine Arabinoside and Methotrexate in Man
1969
Next Generation of Immunotherapy for Melanoma
2008
IMMUNOTHERAPY FOR METASTATIC RENAL CELL CARCINOMA
1993
Histologic correlates of virulence in ovarian adenocarcinoma
1982
Vaccinia virus, herpes simplex virus, and carcinogens induce DNA amplification in a human cell line and support replication of a helpervirus dependent parvovirus
1986 StandoutNobel
Electrochemical Sensor for Ultrasensitive Determination of Doxorubicin and Methotrexate Based on Cyclodextrin‐Graphene Hybrid Nanosheets
2011
In Vivo Targeting of Antigens to Maturing Dendritic Cells via the DEC-205 Receptor Improves T Cell Vaccination
2004 StandoutNobel
Pharmaceuticals of Emerging Concern in Aquatic Systems: Chemistry, Occurrence, Effects, and Removal Methods
2019 Standout
HIV Gag mRNA Transfection of Dendritic Cells (DC) Delivers Encoded Antigen to MHC Class I and II Molecules, Causes DC Maturation, and Induces a Potent Human In Vitro Primary Immune Response
2000 StandoutNobel
Immunotherapy: Bewitched, Bothered, and Bewildered No More
2004 StandoutScienceNobel
Survival and Prognostic Stratification of 670 Patients With Advanced Renal Cell Carcinoma
1999 Standout
Inhibition of HIV-1 Infection by Small Interfering RNA-Mediated RNA Interference
2002 StandoutNobel
Medication Adherence
2009 Standout
Differential N-Linked Glycosylation of Human Immunodeficiency Virus and Ebola Virus Envelope Glycoproteins Modulates Interactions with DC-SIGN and DC-SIGNR
2002 StandoutNobel
Time limitations in the reversal by citrovorum factor of methotrexate-induced immunosuppression in mice
1977
Effect of acyclovir on various murine in vivo and in vitro immunologic assay systems
1982 StandoutNobel
Cisplatin
1984 Standout
Prospective Randomized Trial of Interferon Alfa-2a Plus Vinblastine Versus Vinblastine Alone in Patients With Advanced Renal Cell Cancer
1999
Adjuvant Methotrexate and Citrovorum-Factor Treatment of Osteogenic Sarcoma
1974
Preventing and Managing Toxicities of High-Dose Methotrexate
2016 Standout
Works of Mitchell Ms being referenced
Recombinant interferon alpha-2 (INTRON A) in a phase II study of renal cell carcinoma.
1986
Effectiveness of high-dose infusions of methotrexate followed by leucovorin in carcinoma of the head and neck.
1968
Perspective on allogeneic melanoma lysates in active specific immunotherapy.
1998
Improved therapeutic index of methotrexate with "leucovorin rescue".
1973
New trends in the development of cancer vaccines.
1999
Metabolism of methotrexate in man after high and conventional doses.
1980
The management of depression. Part 2. The place of the new antidepressants.
1994
Cell-mediated immunity and blocking factor in ovarian carcinoma.
1976